A new approach to evaluating drug and chemical safety without animal testing.
The novel 3D body-on-chip developed has an innovative multi-organ design and capillary flow that uniquely facilitates homogenous drug circulation to all organs simultaneously.
A barcoded Synechocystis mutant library and plasmid resource
The project aims to generate a library of thousands of knock-out mutants by generating plasmids targeted to the predicted gene coding sequences of Synechocystis.
The Edinburgh Genome Foundry (EGF) is a research facility specialised in the modular assembly of DNA constructs using a highly automated robotic platform.
University of Edinburgh biotechnology spinout Pheno Therapeutics has announced its lead therapeutic candidate has been cleared as an Investigational New Drug (IND) by the US Food and Drug Administration (FDA), allowing it to move to healthy volunteer studies.
University of Edinburgh spinout Trogenix has announced that the first patient has been dosed in a Phase I/II clinical trial to evaluate its novel gene therapy platform targeting brain cancer.
A macrophage cell therapy that is being developed by spinout Resolution Therapeutics shows promise as the first treatment for advanced liver disease, following results from a clinical trial.
A new contract manufacturing facility at the University of Edinburgh has received Medicines and Healthcare products Regulatory Agency (MHRA) approval to import and manufacture Investigational Medicinal Products for use in human clinical trials.
